Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy / Cognetti, F.; Masetti, R.; Fabi, A.; Bianchi, G.; Santini, D.; Rognone, A.; Catania, G.; Angelucci, D.; Naso, G.; Giuliano, M.; Vassalli, L.; Vici, P.; Scognamiglio, G.; Generali, D.; Zambelli, A.; Colleoni, M.; Tinterri, C.; Scanzi, F.; Vigna, L.; Scavina, P.; Gamucci, T.; Marrazzo, E.; Scinto, A. F.; Berardi, R.; Fabbri, M. A.; Pinotti, G.; Franco, D.; Terribile, D. A.; Tonini, G.; Cianniello, D.; Barni, S.. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - 7:1(2021), p. 47. [10.1038/s41523-021-00246-4]
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
Berardi R.;
2021-01-01
Abstract
Clinicopathological prognostic features have limited value to identify with precision newly diagnosed patients with hormone receptor (HR)-positive, HER2-negative breast cancer (BC), who would benefit from chemotherapy (CT) in addition to adjuvant hormonal therapy (HT). The 21-gene Oncotype DX Breast Recurrence Score® (RS) assay has been demonstrated to predict CT benefit, hence supporting personalized decisions on adjuvant CT. The multicenter, prospective, observational study PONDx investigated the real-life use of RS® results in Italy and its impact on treatment decisions. Physicians’ treatment recommendations (HT ± CT) were documented before and after availability of RS results, and changes in recommendations were determined. In the HR+ HER2− early BC population studied (N = 1738), physicians recommended CT + HT in 49% of patients pre-RS. RS-guided treatment decisions resulted in 36% reduction of CT recommendations. PONDx confirms that RS results provide clinically relevant information for CT recommendation in early-stage BC, resulting in a reduction of more than a third of CT use.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
